cafe

gland malignancy, and when it recurs or metastasizes, we don't have any FDA-approved treatment options. As a result...outcomes and limited therapeutic choices. So the data we're going to discuss are very exciting for this patient...

specific, malignancy. This review aims to discuss the immunological and pathophysiological mechanisms that are thought to be crucial in the aetiology of dysimmune neuropathies as well as their individual electrophysiological...

보장보험에 가입하였고, 같은 해 5.25. ◇◇병원에서 검강검진 결과 자궁 경부세포검사(Pap Smear)상 “정상세포(Negative for malignancy)” 소견을 받음. 2011.2.22 △△산부인과에서 “고등급 편평상피내 병변”소견과 같은 해 3.5 “자궁경부의 침윤성...

triple-negative breast cancer, lung adenocarcinoma, glioblastoma)과 heterogeneity에 따라 다르게 나타납니다. Nat Rev Immunol . Author manuscript; available in PMC: 2024 Sep 1. Published in final edited form as: Nat Rev Immunol. 2024 Apr...

fatality for the patient (Fig. 1). Numerous individuals afflicted with sepsis may experience a comparatively concise phase of hyperinflammation, nonetheless are susceptible to developing immunocompromised states due to extended...

as malignancy, inflammatory disorders, or infection. Participants who had engaged in any structured exercise or physical therapy program for low back pain within the past three months, those utilizing systemic corticosteroids, and those...

a negative correlation between FEL-1 level and duration of DM.83 These findings further support the concept that PEI may be a complication of DM. One study in patients with DM and low FEL-1 (defined as <100 µg/g) showed that PERT reduced...

from malignancy.1 PC has a very poor prognosis with only a 24% one-year survival rate and 9% at 5 years.2 Survival in PC is mainly influenced by stage at diagnosis; in patients with an early stage (around 10% at the diagnosis), surgical...

aggressive malignancy with poor prognosis. Cholangiocarcinoma accounts for approximately 20% of all hepatobiliary malignancies and it can be classified as intrahepatic and extrahepatic cholangiocarcinoma (Tyson and El-Serag, 2011Palmer...